Compounded GIP/GLP-1 dual agonist (tirzepatide)

Compounded Tirzepatide for Women: Status and Cautions

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP · Updated July 2026

Quick answer

Compounded tirzepatide is a pharmacy-mixed version of the drug in Zepbound and Mounjaro. It is not FDA-approved, and availability fell after the FDA removed tirzepatide from its shortage list in late 2024, sharply limiting compounding. Potency and safety are not FDA-verified, and the branded oral-contraceptive caution still applies in principle.

How it works

The active ingredient is tirzepatide, working like branded Zepbound and Mounjaro. Because compounded products are prepared by pharmacies rather than made under FDA approval, purity, dose accuracy, and formulation are not FDA-reviewed.

FDA status for weight: Not FDA-approved. Compounded drugs are not reviewed by the FDA. Compounding became legally restricted after the FDA removed tirzepatide from its shortage list in late 2024.

Women-specific considerations

These are factual notes from FDA labels and published guidelines, not personal medical advice. Discuss your situation with a licensed clinician.

Oral birth control

The branded tirzepatide label warns it may reduce oral-contraceptive effectiveness. With a compounded product of unverified dose, this caution is harder to apply, so a non-oral or barrier method is worth discussing with a clinician.

Unverified potency

Dose accuracy is not FDA-verified, adding uncertainty to any dosing-dependent guidance, including pregnancy planning.

Pregnancy and breastfeeding

The same tirzepatide cautions apply in principle: stop before a planned pregnancy and avoid while breastfeeding.

PCOS

There is no FDA approval for compounded tirzepatide in PCOS or any indication. Any use is off-label and outside FDA review.

Who it is for (eligibility)

There is no FDA eligibility standard for compounded tirzepatide. Legitimate compounding is now limited to specific clinical situations under a licensed prescriber and pharmacy. FDA-approved options are Zepbound (weight) and Mounjaro (diabetes).

Cost (cited)

Cash-pay (503A pharmacies, now largely ended)

Varied by pharmacy; access ended after FDA resolved the shortage

FDA — Compounding and the FDA: Questions and Answers ↗

Current availability

Pricing varies (restricted)

FDA — Compounding and the FDA: Questions and Answers ↗

See the full cost breakdown in our cost guide.

Related questions

Frequently asked questions

Is compounded tirzepatide still available in 2026?
Availability is sharply limited. The FDA removed tirzepatide from its shortage list in late 2024, which restricts large-scale compounding to specific clinical situations only.
Does compounded tirzepatide affect birth control?
The branded tirzepatide label warns of reduced oral-contraceptive effectiveness. Because compounded doses are not FDA-verified, discussing a non-oral or barrier method with a clinician is reasonable.
What are the FDA-approved alternatives?
Zepbound (tirzepatide) is FDA-approved for weight, and Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Both are manufactured under FDA approval, unlike compounded products.

Sources

Every claim above resolves to an FDA label, published trial, guideline, or manufacturer / GoodRx pricing page. External links open in a new tab.

For the general (non women-specific) mechanism, dosing, and side-effect incidence, see our tirzepatide medication overview.

Compare other options

ClearHormones updates this explainer as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.